Ivacaftor affects the susceptibility of standard-of-care drugs used to treat <i>Mycobacterium abscessus</i> lung disease
Patients with cystic fibrosis have dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR), and this predisposes them to nontuberculous mycobacteria (NTM), including <i>Mycobacterium abscessus</i> (MAB)<i>,</i> infection. We found that one of the CFTR modulators, ivacaftor, kills MAB in a concentration-dependent manner, with killing efficacy comparable to amikacin and imipenem, drugs in guideline-based regimens. Using clinical isolates of MAB, amikacin 1/4× MIC concentration combined with ivacaftor killed 2.67 log<sub>10</sub> CFU/mL MAB.
Authors
- Anju Shrivastava (ORCID: https://orcid.org/0000-0003-1796-2065)
- Shashikant Srivastava (ORCID: https://orcid.org/0000-0002-8786-8851)
- Gunavanthi D. Boorgula (ORCID: https://orcid.org/0000-0003-1749-3705)
- Sanjay Singh (ORCID: https://orcid.org/0000-0003-4601-5673)
- Rafael Gálvez (ORCID: https://orcid.org/0000-0002-5384-9919)
Institutions
- The University of Texas at Tyler (US)
- The University of Texas Health Science Center at Tyler (US)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1128/aac.00030-25
- Citations
- 2
- Primary Topic
- Mycobacterium research and diagnosis
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Cystic Fibrosis Foundation
- National Institute of Allergy and Infectious Diseases